Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lowered its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,371,725 shares of the life sciences company’s stock after selling 32,124 shares during the period. Dimensional Fund Advisors LP owned 3.07% of Integra LifeSciences worth $53,790,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership increased its holdings in Integra LifeSciences by 7.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock valued at $312,000 after buying an additional 913 shares in the last quarter. Quadrant Capital Group LLC increased its stake in Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 1,371 shares in the last quarter. Sterling Capital Management LLC raised its holdings in Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock worth $49,000 after purchasing an additional 1,931 shares during the last quarter. Covestor Ltd boosted its position in Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock worth $123,000 after purchasing an additional 2,071 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after purchasing an additional 2,800 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $16.85 on Friday. The company has a 50-day simple moving average of $19.94 and a 200-day simple moving average of $22.10. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The company has a market cap of $1.30 billion, a PE ratio of -187.20, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. Integra LifeSciences Holdings Co. has a 12 month low of $14.45 and a 12 month high of $32.66.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. During the same period last year, the company earned $0.89 EPS. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. On average, equities analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on IART shares. Truist Financial decreased their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $22.71.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.